Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02125929
Other study ID # PUMCHGS2013
Secondary ID ENRLO
Status Completed
Phase N/A
First received April 26, 2014
Last updated August 4, 2015
Start date April 2014
Est. completion date December 2014

Study information

Verified date August 2015
Source Peking Union Medical College Hospital
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To determine the efficacy and safety of robotic, laparoscopic and open surgery for enucleation of benign pancreatic neuroendocrine tumors


Description:

The study was prospective and retrospective, non-randomized study included patients with benign pancreatic neoplasms. The robotic arm consecutively includes patients underwent robotic enucleation surgery and expected number in this arm is 50. The laparoscopic and open surgery arms retrospectively include case from the year 2004. The number of patients for laparoscopic and open surgery arms are 50 and 100, respectively.


Recruitment information / eligibility

Status Completed
Enrollment 156
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- 18-80 years old

- Body Mass Index<30

- Preoperative diagnosis of resectable benign Pancreatic Neuroendocrine Tumors

- Tumor type: Non-functional pancreatic endocrine tumours and insulinomas

- largest diameter < 4cm

- Preoperative CT showed no evidence that tumor was connected with main pancreatic duct

Exclusion Criteria:

- Severe cardio/pulmonary complications

- Other pancreatic diseases, including pancreatitis and pancreatic cancer

- Multiple pancreatic neuroendocrine tumors

- Distant metastasis

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Procedure:
Robotic surgery
Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
Laparoscopic surgery
Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
Open surgery
Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors

Locations

Country Name City State
China Department of General Surgery, Peking Union medical school hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Intra-operative bleeding volume intra operative Yes
Other Operation Time Intra operative No
Other Conversion rate to open surgery Only applied to the robotic surgery arm and laparoscopic arm Intra operative No
Other Quality of life and pain scores up to 30 days No
Other Delayed gastric emptying rate up to 30 days Yes
Other Intra-abdominal bleeding rate up to 30 days Yes
Other Postoperative infection rate up to 30 days Yes
Other Hospital stay time up to 30 days No
Primary Pancreatic fistula rate up to 30 days Yes
Secondary Mortality rate up to 30 days Yes
See also
  Status Clinical Trial Phase
Recruiting NCT03053999 - Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Completed NCT02586844 - Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
Terminated NCT00947167 - A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors Phase 2
Completed NCT02842749 - Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Phase 4
Completed NCT01384617 - Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy N/A
Unknown status NCT01381822 - Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors Phase 1
Completed NCT02841865 - Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Completed NCT01121562 - Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT02685553 - Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project Phase 1
Completed NCT02282059 - The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Terminated NCT01648465 - Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors Phase 2
Terminated NCT02110563 - Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Phase 1